{
    "nct_id": "NCT05238922",
    "official_title": "A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors",
    "inclusion_criteria": "* Adults aged 18 years or older at the time of the signing of the ICF.\n* Life expectancy greater than 12 weeks.\n* ECOG performance status score of 0 or 1.\n* Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available treatment to improve the disease outcome.\n* Availability of a baseline archival tumor specimen or willingness to undergo a pretreatment and an on-treatment tumor biopsy.\n\nFor Part 1:\n\nParticipants in Part 1A (dose escalation): Histologically or cytologically confirmed advanced or metastatic solid tumors.\n\nParticipants in Part 1B (dose expansion):\n\n* Disease Group 1: Ovarian/Fallopian/Primary Peritoneal Cancer\n* Disease Group 2: Endometrial/Uterine Cancer\n* Disease Group 3: Gastric, GEJ, and esophageal carcinomas\n* Disease Group 4: TNBC\n* Disease Group 5: HR+/HER2- breast cancer\n* Disease Group 6: Other tumor indications excluding bone cancers\n\nFor Part 2:\n\nParticipants in Part 2A (dose escalation): Histologically or cytologically confirmed advanced or metastatic solid tumors.\n\n* TGA, TGC, TGE, TGF, and TGG: Participants with HR+/HER2- breast cancer or participants with a different tumor.\n* TGB and TGD: Participants with HR+/HER2- breast cancer.\n\nParticipants in Part 2b (dose expansion):\n\n* TGH and TGJ:\n\n  * Participants with HR+/HER2- breast cancer.\n  * Participants with any other advanced or metastatic solid tumor.\n* TGI and TGK:\n\n  • Participants with HR+/HER2- breast cancer.\n* TGL, TGM and TGN:\n\n  • Participants with advanced or metastatic epithelial ovarian/fallopian/primary peritoneal carcinoma.\n* Measurable lesions by CT or MRI based on RECIST v1.1 criteria.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of clinically significant or uncontrolled cardiac disease.\n* History or presence of an ECG abnormality that, in the investigator's opinion, is clinically meaningful.\n* Presence of chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.\n* Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed.\n* Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of the first dose of study drug.\n* Specific laboratory values.\n* Significant concurrent, uncontrolled medical conditions, including but not limited to Hepatic and Gastrointestinal.\n* Has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study drug.\n* Prior treatment with any CDK2 inhibitor.\n* Any change in endocrine therapy within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug or any administration of targeted therapy, antibody, or hypomethylating agent to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug.\n* Any major surgery within 28 days before the first dose of study drug.\n* Any prior radiation therapy within 28 days before the first dose of study drug.\n* Undergoing treatment with another investigational medication or having been treated with an investigational medication within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug.\n* Active HBV or HCV infection that requires treatment.\n* Known history of HIV.\n* Known hypersensitivity or severe reaction to any component of study treatment or formulation components.\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply.",
    "miscellaneous_criteria": ""
}